title: How molecular profiling could revolutionize drug discovery.
abstract: Information from genomic, proteomic and metabolomic measurements has already benefited target discovery and validation, assessment of efficacy and toxicity of compounds, identification of disease subgroups and the prediction of responses of individual patients. Greater benefits can be expected from the application of these technologies on a significantly larger scale; by simultaneously collecting diverse measurements from the same subjects or cell cultures; by exploiting the steadily improving quantitative accuracy of the technologies; and by interpreting the emerging data in the context of underlying biological models of increasing sophistication. The benefits of applying molecular profiling to drug discovery and development will include much lower failure rates at all stages of the drug development pipeline, faster progression from discovery through to clinical trials and more successful therapies for patient subgroups. Upheavals in existing organizational structures in the current 'conveyor belt' models of drug discovery might be required to take full advantage of these methods.
authors.affiliation: GHC Technologies, Inc., 505 Coast Boulevard South, Suite 309, La Jolla, California 92037, USA. roland_stoughton@ghctechnologies.com
authors.forename: Roland B
authors.initials: RB
authors.lastname: Stoughton
authors.forename: Stephen H
authors.initials: SH
authors.lastname: Friend
mesh_terms: D000818:Animals; D015195:Drug Design; D020869:Gene Expression Profiling; D006801:Humans; D010597:Pharmacogenetics; D040901:Proteomics